The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Dyspepsia


Psychiatry related information on Dyspepsia


High impact information on Dyspepsia

  • METHODS: We randomly assigned 170 H. pylori-infected patients with nonulcer dyspepsia to receive twice-daily treatment with 20 mg of omeprazole, 1000 mg of amoxicillin, and 500 mg of clarithromycin for 14 days and 167 such patients to receive identical-appearing placebos; all patients were then followed through regular visits for 12 months [7].
  • CONCLUSIONS: In patients with H. pylori infection and nonulcer, or functional, dyspepsia, treatment with omeprazole and antibiotics to eradicate the infection is more likely to resolve symptoms than treatment with omeprazole alone [8].
  • Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia [9].
  • The most common adverse events were headache (11% sildenafil, 2% placebo), dyspepsia (9% sildenafil, 0% placebo), and respiratory tract disorder (6% sildenafil, 2% placebo), predominantly sinus congestion or drainage [10].
  • CONCLUSIONS: Prompt endoscopy confers a small benefit in terms of cure of dyspepsia but costs more than "test and treat" and is not a cost-effective strategy for the initial management of dyspepsia [11].

Chemical compound and disease context of Dyspepsia

  • METHODS: Patients were enrolled if they were NSAID naïve, had a positive urea breath test, had dyspepsia or an ulcer history, and required long-term NSAID treatment [12].
  • Endoscopy was repeated after 8 weeks of naproxen treatment or when naproxen treatment was stopped early because of bleeding or intractable dyspepsia [13].
  • Dicyclomine for idiopathic dyspepsia [14].
  • The results showed that whereas pentagastrin caused a significant increase in gastric secretion, only the patients with nonulcer dyspepsia reported any appreciable pain before or after the injection [15].
  • While NSAIDs also cause dyspepsia, inhibition of prostaglandin synthesis may reduce this from even higher levels that would otherwise prevail and mask ulcer-related dyspepsia, making anticipatory management difficult [16].

Biological context of Dyspepsia


Anatomical context of Dyspepsia


Gene context of Dyspepsia

  • BACKGROUND & AIMS: In patients with functional dyspepsia, altered alpha-adrenoreceptor function and depression are prevalent, features that are linked to a G-protein beta 3 (GNB3) subunit gene polymorphism (C825T) [27].
  • Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia [28].
  • RESULTS: COX-2 expression in corpus was significantly higher in H. pylori positive than in negative non-ulcer dyspepsia (NUD) (p <.05) [29].
  • CCK is a major mediator of the sensitisation of gastric perception by lipids in patients with functional dyspepsia as the CCK-A receptor antagonist dexloxiglumide markedly diminishes this effect [30].
  • Similarly, the 120 kDa antigen (cagA) tended (p < 0.15) to be more prevalent in DU patients (82%; 95% CI, 69-91) compared with controls (69%; 95% CI, 57-80) but not functional dyspepsia (77%; 95% CI, 57-90) [31].

Analytical, diagnostic and therapeutic context of Dyspepsia

  • Unadjusted rates of GI hospitalization, ulcer, and dyspepsia were higher for patients in the acetaminophen cohort than for those in the NSAID cohort [32].
  • METHOD: Patients with a clinical diagnosis of functional dyspepsia according to the Rome II criteria and normal upper gastrointestinal endoscopy were recruited and randomised to receive: (1) lansoprazole 30 mg, (2) lansoprazole 15 mg, or (3) placebo, all given daily for four weeks [33].
  • The total incidence of nausea, vomiting, diarrhoea and dyspepsia in a double-blind study was 12% in patients who received tranexamic acid 1g four times daily for 4 days for two cycles (not significantly different to the incidence in placebo recipients) [34].
  • Although originally developed for the assessment of uninvestigated dyspepsia, the validation of SODA for use in clinical trials suggested its ability to compare treatment effects of non-specific non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX)-2-specific inhibitors [35].
  • METHODS: Forty-three healthy volunteers and 10 patients with functional dyspepsia received motilin (4 pmol.min/kg) or placebo in four separate double-blind, randomized, placebo-controlled, cross-over studies [24].


  1. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. Blum, A.L., Talley, N.J., O'Moráin, C., van Zanten, S.V., Labenz, J., Stolte, M., Louw, J.A., Stubberöd, A., Theodórs, A., Sundin, M., Bolling-Sternevald, E., Junghard, O. N. Engl. J. Med. (1998) [Pubmed]
  2. Five-year study of cimetidine or surgery for severe duodenal ulcer dyspepsia. Gray, G.R., McWhinnie, D., Smith, I.S., Gillespie, G. Lancet (1982) [Pubmed]
  3. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori. Loeb, D.S., Talley, N.J., Ahlquist, D.A., Carpenter, H.A., Zinsmeister, A.R. Gastroenterology (1992) [Pubmed]
  4. Dyspepsia and dyspepsia subgroups: a population-based study. Talley, N.J., Zinsmeister, A.R., Schleck, C.D., Melton, L.J. Gastroenterology (1992) [Pubmed]
  5. Diagnostic value of an immunoassay to detect anti Campylobacter pylori antibodies in non-ulcer dyspepsia. Loffeld, R.J., Stobberingh, E., Flendrig, J.A., van Spreeuwel, J.P., Arends, J.W. Lancet (1989) [Pubmed]
  6. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Schrag, A.E., Brooks, D.J., Brunt, E., Fuell, D., Korczyn, A., Poewe, W., Quinn, N.P., Rascol, O., Stocchi, F. Clinical neuropharmacology. (1998) [Pubmed]
  7. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. Talley, N.J., Vakil, N., Ballard, E.D., Fennerty, M.B. N. Engl. J. Med. (1999) [Pubmed]
  8. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. McColl, K., Murray, L., El-Omar, E., Dickson, A., El-Nujumi, A., Wirz, A., Kelman, A., Penny, C., Knill-Jones, R., Hilditch, T. N. Engl. J. Med. (1998) [Pubmed]
  9. Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. Nyrén, O., Adami, H.O., Bates, S., Bergström, R., Gustavsson, S., Lööf, L., Nyberg, A. N. Engl. J. Med. (1986) [Pubmed]
  10. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. Rendell, M.S., Rajfer, J., Wicker, P.A., Smith, M.D. JAMA (1999) [Pubmed]
  11. Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Ford, A.C., Qume, M., Moayyedi, P., Arents, N.L., Lassen, A.T., Logan, R.F., McColl, K.E., Myres, P., Delaney, B.C. Gastroenterology (2005) [Pubmed]
  12. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Chan, F.K., To, K.F., Wu, J.C., Yung, M.Y., Leung, W.K., Kwok, T., Hui, Y., Chan, H.L., Chan, C.S., Hui, E., Woo, J., Sung, J.J. Lancet (2002) [Pubmed]
  13. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Chan, F.K., Sung, J.J., Chung, S.C., To, K.F., Yung, M.Y., Leung, V.K., Lee, Y.T., Chan, C.S., Li, E.K., Woo, J. Lancet (1997) [Pubmed]
  14. Dicyclomine for idiopathic dyspepsia. Stephens, C.J., Lever, L., Hoare, A.M. Lancet (1988) [Pubmed]
  15. Blocked and nonblocked acid secretion and reported pain in ulcer, nonulcer dyspepsia, and normal subjects. Bates, S., Sjödén, P.O., Fellenius, J., Nyrén, O. Gastroenterology (1989) [Pubmed]
  16. Nonsteroidal anti-inflammatory drug gastropathy. Hawkey, C.J. Gastroenterology (2000) [Pubmed]
  17. Measurement of gastric emptying in dyspeptic patients: effect of a new gastrokinetic agent (cisapride). Jian, R., Ducrot, F., Piedeloup, C., Mary, J.Y., Najean, Y., Bernier, J.J. Gut (1985) [Pubmed]
  18. Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study. Kang, J.Y., Tay, H.H., Wee, A., Guan, R., Math, M.V., Yap, I. Gut (1990) [Pubmed]
  19. The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected]. Mason, I., Millar, L.J., Sheikh, R.R., Evans, W.M., Todd, P.L., Turbitt, M.L., Taylor, M.D. Aliment. Pharmacol. Ther. (1998) [Pubmed]
  20. Effects of oral clarithromycin and amoxycillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. Bortolotti, M., Brunelli, F., Sarti, P., Mari, C., Miglioli, M. Aliment. Pharmacol. Ther. (1998) [Pubmed]
  21. The effects of levosulpiride on gastric and gall-bladder emptying in functional dyspepsia. Arienti, V., Corazza, G.R., Sorge, M., Boriani, L., Ugenti, F., Biagi, F., Maconi, G., Sottili, S., Van Thiel, D.H., Gasbarrini, G. Aliment. Pharmacol. Ther. (1994) [Pubmed]
  22. The early diagnosis of gastrinoma. Modlin, I.M., Jaffe, B.M., Sank, A., Albert, D. Ann. Surg. (1982) [Pubmed]
  23. Somatostatin-secreting islet cell tumor (somatostatinoma): suppression of growth hormone (GH) release induced by GH-releasing hormone. Iguchi, H., Kumagai, S., Seo, I.H., Wakasugi, H., Hara, Y., Abe, M. J. Clin. Endocrinol. Metab. (1988) [Pubmed]
  24. Gallbladder volume as a biomarker for the motilin effect in healthy volunteers and patients with functional dyspepsia. Kamerling, I.M., Van Haarst, A.D., De Kam, M.L., Cohen, A.F., Masclee, A.A., Burggraaf, J. Aliment. Pharmacol. Ther. (2004) [Pubmed]
  25. Basophils, histamine and gastric acid secretin in chronic myeloproliferative disorders. Gray, A.G., Boughton, B.J., Burt, D.S., Struthers, G.R. Br. J. Haematol. (1982) [Pubmed]
  26. Nicardipine in the prevention of cerebral infarction. Martí Massó, J.F., Lozano, R. Clinical therapeutics. (1990) [Pubmed]
  27. G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Holtmann, G., Siffert, W., Haag, S., Mueller, N., Langkafel, M., Senf, W., Zotz, R., Talley, N.J. Gastroenterology (2004) [Pubmed]
  28. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Feinle, C., Meier, O., Otto, B., D'Amato, M., Fried, M. Gut (2001) [Pubmed]
  29. Effect of Helicobacter pylori-induced cyclooxygenase-2 on gastric epithelial cell kinetics: implication for gastric carcinogenesis. Wambura, C., Aoyama, N., Shirasaka, D., Sakai, T., Ikemura, T., Sakashita, M., Maekawa, S., Kuroda, K., Inoue, T., Ebara, S., Miyamoto, M., Kasuga, M. Helicobacter (2002) [Pubmed]
  30. The role of fat and cholecystokinin in functional dyspepsia. Fried, M., Feinle, C. Gut (2002) [Pubmed]
  31. Antibody response to specific H. pylori antigens in functional dyspepsia, duodenal ulcer disease, and health. Holtmann, G., Talley, N.J., Mitchell, H., Hazell, S. Am. J. Gastroenterol. (1998) [Pubmed]
  32. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. Rahme, E., Pettitt, D., LeLorier, J. Arthritis Rheum. (2002) [Pubmed]
  33. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Wong, W.M., Wong, B.C., Hung, W.K., Yee, Y.K., Yip, A.W., Szeto, M.L., Fung, F.M., Tong, T.S., Lai, K.C., Hu, W.H., Yuen, M.F., Lam, S.K. Gut (2002) [Pubmed]
  34. Tranexamic acid: a review of its use in the management of menorrhagia. Wellington, K., Wagstaff, A.J. Drugs (2003) [Pubmed]
  35. Measuring dyspepsia-related health in randomized trials: the Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX-2-specific inhibitors. Rabeneck, L. Rheumatology (Oxford, England) (2003) [Pubmed]
WikiGenes - Universities